Corteria Investors

Corteria Financial Partners

Kurma Partners Founded in 2009 and based in Paris, Kurma Partners is a key European player in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III and Kurma Diagnostics and Kurma Diagnostics 2, as well as the links the company has forged with a network of prestigious research institutes and hospitals

V-Bio Ventures V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world’s premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.

Omnes Capital Omnes is a leading private equity and infrastructure investor. With €5 billion in assets under management, it provides companies with the capital they need to fund their growth, in three key areas: venture capital, growth & buyout capital and infrastructure. Omnes is wholly-owned by its employees. It is committed to ESG factors and has founded the Fondation Omnes to fund initiatives in favour of children and young people. It is a signatory to the United Nations Principles for Responsible Investment (PRI). 

Invivo Capital Invivo Capital Partners is a Spanish venture capital firm founded by Dr. Lluís Pareras and Albert Ferrer, which manages Invivo Ventures FCR, venture capital fund that invests in life-science companies at an early stage. Invivo Ventures FCR has a majority of private investors with the support of a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Global, the Institut Català de Finances, the Institut Valencià de Finances and the Ajuntament de Barcelona.

Fountain Healthcare Partners Fountain Healthcare Partners is a European life science venture capital fund with offices in Dublin and New York. Founded in 2008, Fountain is Ireland’s largest dedicated life science venture capital fund with more than €300 million under management across three funds. Fountain invests in entrepreneurs and companies with disruptive technologies or products that have a clear pharmacoeconomic benefit and a defined pathway to commercialisation, value enhancement and exit.

Board of Directors

Thierry Laugel (Chair) from Kurma Partners
Thierry Laugel co-founded Kurma Partners in 2009 and currently serves as managing partner. Additionally, he is currently a board member of Corteria Pharma, Amolyt Pharma, Ermium, Coave Therapeutics, Minoryx, Blink Biomedical and Pathoquest, and is President of Argobio Studio. Dr. Laugel started his career in the industry (Laboratoires Fournier and Flamel Technologies), before moving to investments (Caisse des Dépôts and then AGF Private Equity) before launching Kurma. Dr. Laugel has led investments in more than 25 companies. He earned his PharmD from Strasbourg University, Ph.D. from Paris South University and MBA from INSEAD.

Peter Neubeck from Kurma Partners
Peter is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School and holds an MBA from INSEAD. After tenures at Großhadern University Clinic, Cleveland Clinic, and Beth Israel Deaconess Hospital followed by McKinsey & Company and several leadership positions at Novartis, he entered the Venture Capital industry. He took on responsibilities as an Investment Manager and collected valuable operational experience in various executive roles in company creations. Since January 2019 he heads the investment business of Kurma Partners in Germany

Ward Capoen from V-Bio Ventures
Ward is Principal at V-Bio Ventures, which he joined in 2016. He has a PhD in molecular biology from VIB/Ugent, and held research positions at the John Innes Centre and Harvard Medical School. Prior to V-Bio Ventures, Ward worked as a senior analyst at Candriam Investors Group in Brussels.

Claire Poulard from Omnes
Claire Poulard joined Omnes Venture team specializing in Life Sciences in 2015. She began her career in research at the Singapore Institute for Neurotechnology. Claire Poulard holds a master's degree in Pharmaceutical Management and Biotechnology from ESCP Europe and a master in Bioengineering and Neuroscience Innovation from ESPCI (Ecole Supérieure de Physique et Chimie Industrielle).

Luis Pareras from Invivo Capital
Luis is the founding Partner of two Venture Capital funds (Healthequity and Invivo Ventures) focused in early-stage investments in the healthcare sector, where he has led the investment strategy and transaction processes. He serves or has served at the Board of Directors of many life-sciences companies including Sanifit, Minoryx, Versantis, Glycardial Diagnostics, n-Life Therapeutics, Peptomyc, Arthex, Pulmobiotics, Gyala, Telum, OneChain Immunotherapeutics, Telomere Therapeutics and Corteria. Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations, and author of numerous books in the field of innovation, venture capital and healthcare. In the academic space, he teaches at several business schools about healthcare innovation and venture capital.
Degree and PhD in Medicine (UB), specialist in Neurosurgery and Global Executive MBA (IESE).

Aidan King from Fountain Healthcare Partners
Aidan co-founded Fountain Healthcare Partners in 2008 and currently serves as a managing partner. Aidan is a pharmacist by training and started his industry career at Elan Corporation in pharmaceutical strategic marketing and business development before moving to New York to work in Elan’s corporate venture capital group. Aidan is a CFA charterholder and has led investments in over 30 private and public life science companies in the US and Europe.

Marc Semigran MD, PhD
Marc Semigran, MD is a cardiologist with subspecialty expertise in cardiomyopathy, heart failure, and cardiac transplantation.
He was Senior Vice President of Medical Sciences and Chief Medical Officer at MyoKardia (acquired by Bristol Myers Squibb in Nov. 2020). There, he led the early development of mavacamten for the treatment of hypertrophic cardiomyopathy, as well as development of other pipeline agents for the treatment of cardiomyopathy. Prior to joining MyoKardia, Dr. Semigran led the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital as Section Head and Medical Director. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General Hospital for more than 25 years and as associate professor at Harvard Medical School. Dr. Semigran has published numerous peer-reviewed papers, received many research awards, served as a principal investigator in major clinical trials, and served in scientific and medical advisory capacities to companies such as GSK, Medtronic, and Bayer. Dr. Semigran earned AB, AM and MD degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital.